jumped early Tuesday after the biotech and its partner
announced positive results for a phase II study of their anti-constipation drug Entereg.
The study, known as SB-767905/011, covered 522 noncancer patients with opioid-induced bowel dysfunction, or OBD, and showed that all three oral Entereg dosage regimens achieved statistically significant effects on the primary and secondary endpoints compared with placebo.
"We believe that the changes seen are clinically important and provide the platform for the development of an important new therapy for patients with OBD, the companies said in a statement.
Shares in Pennsylvania-based Adolor traded at $10.46, up $1.64, or 18.6%, in the premarket. U.S. shares of U.K.-based Glaxo closed at $48.41 Monday.